Clinical Trials
- Leukemia
test
- Leukemia
The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Leukemia
test
- Sarcoma Cancers, Brain and Other Nervous System Cancers, Other Cancers, Lymphoma, Kidney Cancer, Leukemia, Liver Cancer, Stomach and Esophagus, Thyroid and Other Endocrine Cancers, Gynecological Cancers, Lung Cancer, Bladder Cancer, Colorectal Cancer, Pediatric Cancers
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
- Leukemia, Pediatric Cancers
test
- Phase 1 Cancers
test
- Lymphoma, Leukemia
Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
- Leukemia
test
- Ages1 year - 25 years
- GenderBoth
- Phase 1 Cancers
test
- Lung Cancer
test